Trial reportAIDS (London, England)2007
Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.
Trial report in AIDS (London, England), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00525239 (HIV Antiretroviral Drugs and Metabolism), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
HIV Antiretroviral Drugs and Metabolism
Who cites it
25 citing papers in PubMed, 62 citations in OpenAlex.
- TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- Trial
- Trial
- Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.Journal of acquired immune deficiency syndromes (1999) · 2010Trial
- The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men.Journal of acquired immune deficiency syndromes (1999) · 2009Trial
- Metabolic Dysfunction-Associated Steatotic Liver Disease in People Living with HIV-Limitations on Antiretroviral Therapy Selection.Life (Basel, Switzerland) · 2024Review
- Liver insulinization as a driver of triglyceride dysmetabolism.Nature metabolism · 2023Review
- Optimized pharmacological control over the AAV-Gene-Switch vector for regulable gene therapy.Molecular therapy. Methods & clinical development · 2021Article
- Liver Fibrosis during Antiretroviral Treatment in HIV-Infected Individuals. Truth or Tale?Cells · 2021Review
- COVID-19 and diabetes mellitus: from pathophysiology to clinical management.Nature reviews. Endocrinology · 2021Review
- HIV Protease Inhibitors and Insulin Sensitivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Frontiers in pharmacology · 2021Review
- A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing?Infectious diseases and therapy · 2019Review
- Telmisartan reverses antiretroviral-induced adipocyte toxicity and insulin resistance in vitro.Diabetes & vascular disease research · 2018Article
- Metabolic and Cardiac Adaptation to Chronic Pharmacologic Blockade of Facilitative Glucose Transport in Murine Dilated Cardiomyopathy and Myocardial Ischemia.Scientific reports · 2018Article
- Hemeoxygenase-1 as a Novel Driver in Ritonavir-Induced Insulin Resistance in HIV-1-Infected Patients.Journal of acquired immune deficiency syndromes (1999) · 2017Article
- Brachial and central blood pressure in HIV-infected subjects.Hypertension research : official journal of the Japanese Society of Hypertension · 2015Article
- The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care.Current HIV/AIDS reports · 2012Review
- GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system.Antimicrobial agents and chemotherapy · 2011Article
- Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.The Journal of pharmacology and experimental therapeutics · 2010Article
- Antiretroviral therapy in the clinic.Journal of virology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundSome HIV protease inhibitors (PIs) have been shown to induce insulin resistance in vitro but the degree to which specific PIs affect insulin sensitivity in humans is less well understood.
methodsIn two separate double-blind, randomized, cross-over studies, we assessed the effects of a single dose of ritonavir (800 mg) and amprenavir (1200 mg) on insulin sensitivity (euglycemic hyperglycemic clamp) in healthy normal volunteers.
resultsRitonavir decreased insulin sensitivity (-15%; P = 0.008 versus placebo) and non-oxidative glucose disposal (-30%; P = 0.0004), whereas neither were affected by amprenavir administration.
conclusionCompared to previously performed studies of identical design using single doses of indinavir and lopinavir/ritonavir, a hierarchy of insulin resistance was observed with the greatest effect seen with indinavir followed by ritonavir and lopinavir/ritonavir, with little effect of amprenavir.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.